34
Views
5
CrossRef citations to date
0
Altmetric
Research Article

Labelling of bleomycin with Auger-emitter increases cytotoxicity in squamous-cell cancer cell lines

Pages 565-570 | Published online: 03 Jul 2009
 

Abstract

Purpose: To investigate the cytotoxicity of bleomycin (BLM), two Auger-emitting bleomycin complexes (indium-111 (111In)-BLMC) and 111InCl3 in three squamous cell cancer (SCC) cell lines. Material and methods: Three recently established SCC cell lines were investigated using the 96-well clonogenic assay. Concentrations causing 50% inhibition in cell survival (IC) were calculated for BLM and two specific activities of 111In BLMC (40 MBq/mg BLM (low) and 195 MBq/mg BLM (high)). Results: 111In-BLMC (low) was the most toxic to the SCC cell lines. 111In-BLMC containing 4.9-fold more activity of 111In (195 MBq/mg BLM) was more effective than BLM (p=0.0029), but not as toxic as 111In-BLMC (low) (p=0.0023). UT-SCC-19A had a IC50 value for BLM as low as 4.1 nm, whereas IC50 values for 111In-BLMC (low) and 111In-BLMC (high) were 2.0 nm and 2.6 nm, respectively. The most chemoresistant cell line UT-SCC-12A had a IC value for BLM of 18.8 nm, for 111In50 BLMC (low) 10.7 nm and for 111In-BLMC (high) 12.7 nm. 111InCl3 had no cell killing effect. Conclusions: This study shows that 111In-BLMC is superior in SCC cell killing compared with BLM. These data provide the basis for further clinical investigations of 111In-BLMC.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.